Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
02 October 2000Website:
http://aspirawh.comNext earnings report:
28 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:59:25 GMTDividend
Analysts recommendations
Institutional Ownership
AWH Latest News
Aspira (AWH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.48 per share a year ago.
Aspira Women's Health Inc. (NASDAQ:AWH ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Nicole Sandford - Chief Executive Officer & Director Sandy Milligan - President John Kallassy - Interim Chief Financial Officer Conference Call Participants Operator Good morning, ladies and gentlemen and welcome to Aspira Women's Health Incorporated Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Achieved $141.6 million Net Revenue in Q3 2024 Reported $25.1 million in Adjusted EBITDA Anticipates $30 million of Annual Savings Through Transformation Initiatives MORRISTOWN, N.J. , Nov. 12, 2024 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH," or the "Company" or "Ascend") (CSE: AAWH.U) (OTCQX: AAWH), a vertically integrated multi-state cannabis operator focused on bettering lives through cannabis, today reported its financial results for the three months ended September 30, 2024 ("Q3 2024").
Event to feature presentations from Dr. Kevin Elias, Dr. Richard Gersh, Dr. Sandra Milligan, and Dr. Todd Pappas on the Company's development pipeline Event to feature presentations from Dr. Kevin Elias, Dr. Richard Gersh, Dr. Sandra Milligan, and Dr. Todd Pappas on the Company's development pipeline
Aspira aims to develop a multi-marker miRNA blood test to aid in the detection of endometriosis Aspira aims to develop a multi-marker miRNA blood test to aid in the detection of endometriosis
New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation (CLEP) approval allows for OvaWatch® to be marketed in New York State New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation (CLEP) approval allows for OvaWatch® to be marketed in New York State
Aspira Womens Health (AWH, Financial) experienced a significant stock price drop of 7.80%, reaching $0.775 per share. The trading volume stood at 14,064 shares with a turnover rate of 0.09% and a volatility of 7.47%.
AWH's partnership with Dorsata is set to help with the adnexal masses diagnosis and treatment.
Aspira (AWH) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.28 per share a year ago.
Q2 2024 OvaSuite S M revenue of $2.4 million and volume of 6,471 units
- 1(current)
What type of business is Aspira Womens Health?
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard's Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University of Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating miRNAs and proteins; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.
What sector is Aspira Womens Health in?
Aspira Womens Health is in the Healthcare sector
What industry is Aspira Womens Health in?
Aspira Womens Health is in the Diagnostics & Research industry
What country is Aspira Womens Health from?
Aspira Womens Health is headquartered in United States
When did Aspira Womens Health go public?
Aspira Womens Health initial public offering (IPO) was on 02 October 2000
What is Aspira Womens Health website?
https://aspirawh.com
Is Aspira Womens Health in the S&P 500?
No, Aspira Womens Health is not included in the S&P 500 index
Is Aspira Womens Health in the NASDAQ 100?
No, Aspira Womens Health is not included in the NASDAQ 100 index
Is Aspira Womens Health in the Dow Jones?
No, Aspira Womens Health is not included in the Dow Jones index
When was Aspira Womens Health the previous earnings report?
No data
When does Aspira Womens Health earnings report?
The next expected earnings date for Aspira Womens Health is 28 March 2025